Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS.

JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.1856. [Epub ahead of print]

PMID:
31393518
2.

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.

Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC.

Mol Cancer Ther. 2019 Aug;18(8):1374-1385. doi: 10.1158/1535-7163.MCT-18-1323. Epub 2019 Jun 12.

PMID:
31189611
3.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; Cancer Genome Atlas Research Network, Hu H.

Cell. 2018 Apr 5;173(2):400-416.e11. doi: 10.1016/j.cell.2018.02.052.

4.

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW.

Cell. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022.

5.

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group.

J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270.

6.

Discovery of internalizing antibodies to basal breast cancer cells.

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD.

Protein Eng Des Sel. 2018 Jan 1;31(1):17-28. doi: 10.1093/protein/gzx063.

7.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC.

Oncotarget. 2016 Oct 18;8(48):83432-83445. doi: 10.18632/oncotarget.12735. eCollection 2017 Oct 13.

8.

Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study.

Powell MJ, Von Behren J, Neuhausen S, Reynolds P, Benz CC.

Cancer Causes Control. 2017 Oct;28(10):1027-1032. doi: 10.1007/s10552-017-0942-7. Epub 2017 Aug 18.

9.

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS.

Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.

10.

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS.

JAMA Oncol. 2017 Nov 1;3(11):1503-1510. doi: 10.1001/jamaoncol.2017.1261. Erratum in: JAMA Oncol. 2017 Nov 1;3(11):1589.

11.

Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.

Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI.

JAMA Oncol. 2017 Dec 1;3(12):1654-1662. doi: 10.1001/jamaoncol.2017.0595.

12.

TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.

Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z.

Oncogene. 2016 Nov 3;35(44):5781-5794. doi: 10.1038/onc.2016.112. Epub 2016 May 2.

13.

Comment on: 'Hypertensive diseases in pregnancy and breast cancer risk'.

Cirillo PM, Benz CC, Cohn BA.

Br J Cancer. 2016 May 24;114(11):e10. doi: 10.1038/bjc.2016.81. Epub 2016 May 3. No abstract available.

14.

DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas.

Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison KH, Beck AH, Yau C, Bowen J, Sheth M, Hwang ES, Perou CM, Laird PW, Ding L, Benz CC.

NPJ Breast Cancer. 2016 May 4;2:16007. doi: 10.1038/npjbcancer.2016.7. eCollection 2016.

15.

A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.

Jupe ER, Dalessandri KM, Mulvihill JJ, Miike R, Knowlton NS, Pugh TW, Zhao LP, DeFreese DC, Manjeshwar S, Gramling BA, Wiencke JK, Benz CC.

BBA Clin. 2014 Nov 8;2:94-102. doi: 10.1016/j.bbacli.2014.11.001. eCollection 2014 Dec.

16.

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.

Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Pourmand N, Benz CC.

Breast Cancer Res Treat. 2015 Nov;154(1):23-32. doi: 10.1007/s10549-015-3589-7. Epub 2015 Oct 12.

PMID:
26456572
17.
18.

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.

Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson PS, Campisi J.

Nat Cell Biol. 2015 Aug;17(8):1049-61. doi: 10.1038/ncb3195. Epub 2015 Jul 6.

19.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

20.

Sources of superoxide/H2O2 during mitochondrial proline oxidation.

Goncalves RL, Rothschild DE, Quinlan CL, Scott GK, Benz CC, Brand MD.

Redox Biol. 2014 Jul 18;2:901-9. doi: 10.1016/j.redox.2014.07.003. eCollection 2014.

21.

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM.

Cell. 2014 Aug 14;158(4):929-944. doi: 10.1016/j.cell.2014.06.049. Epub 2014 Aug 7.

22.

RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.

Wilson-Edell KA, Kehasse A, Scott GK, Yau C, Rothschild DE, Schilling B, Gabriel BS, Yevtushenko MA, Hanson IM, Held JM, Gibson BW, Benz CC.

Oncotarget. 2014 Jul 15;5(13):5165-76.

23.

First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants.

Prebil LA, Ereman RR, Powell MJ, Jamshidian F, Kerlikowske K, Shepherd JA, Hurlbert MS, Benz CC.

Cancer Causes Control. 2014 Jul;25(7):859-68. doi: 10.1007/s10552-014-0386-2. Epub 2014 May 7.

24.

mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.

Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC.

Breast Cancer Res Treat. 2014 Apr;144(2):287-298. doi: 10.1007/s10549-014-2877-y. Epub 2014 Feb 22.

25.

Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.

Zawadzka AM, Schilling B, Cusack MP, Sahu AK, Drake P, Fisher SJ, Benz CC, Gibson BW.

Mol Cell Proteomics. 2014 Apr;13(4):1034-49. doi: 10.1074/mcp.M113.035485. Epub 2014 Feb 6.

26.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC.

Breast Cancer Res. 2013;15(5):R103.

27.

Age-related micro-RNA abundance in individual C. elegans.

Lucanic M, Graham J, Scott G, Bhaumik D, Benz CC, Hubbard A, Lithgow GJ, Melov S.

Aging (Albany NY). 2013 Jun;5(6):394-411.

28.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4. Epub 2013 May 28.

PMID:
23712790
29.

Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple Protease Digestion with Data-Dependent (MS1) and Data-Independent (MS2) Acquisitions.

Held JM, Schilling B, D'Souza AK, Srinivasan T, Behring JB, Sorensen DJ, Benz CC, Gibson BW.

Int J Proteomics. 2013;2013:791985. doi: 10.1155/2013/791985. Epub 2013 Apr 4.

30.

Integrated genomic characterization of endometrial carcinoma.

Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA.

Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113. Erratum in: Nature. 2013 Aug 8;500(7461):242.

31.

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3. Epub 2012 Oct 27.

32.

Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.

Held JM, Britton DJ, Scott GK, Lee EL, Schilling B, Baldwin MA, Gibson BW, Benz CC.

Mol Cancer Res. 2012 Aug;10(8):1120-32. doi: 10.1158/1541-7786.MCR-12-0099. Epub 2012 Jun 5.

33.

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.

Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20.

34.

Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.

Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH Jr.

Clin Cancer Res. 2011 May 1;17(9):2874-84. doi: 10.1158/1078-0432.CCR-10-2334. Epub 2011 Mar 17. Erratum in: Clin Cancer Res. 2011 Nov 1;17(21):6952. Retrouvay, Hélène [corrected to Retrouvey, Hélène].

35.

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.

Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC.

Breast Cancer Res Treat. 2011 Apr;126(3):803-10. doi: 10.1007/s10549-011-1345-1. Epub 2011 Jan 12.

36.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14.

37.

ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.

Marx C, Held JM, Gibson BW, Benz CC.

Cancer Res. 2010 May 1;70(9):3709-17. doi: 10.1158/0008-5472.CAN-09-3768. Epub 2010 Apr 20.

38.

Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach.

Held JM, Danielson SR, Behring JB, Atsriku C, Britton DJ, Puckett RL, Schilling B, Campisi J, Benz CC, Gibson BW.

Mol Cell Proteomics. 2010 Jul;9(7):1400-10. doi: 10.1074/mcp.M900643-MCP200. Epub 2010 Mar 16.

39.

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB.

J Control Release. 2010 Jan 4;141(1):13-21. doi: 10.1016/j.jconrel.2009.08.006. Epub 2009 Aug 15.

PMID:
19686789
40.

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES.

Clin Cancer Res. 2009 May 1;15(9):3163-71. doi: 10.1158/1078-0432.CCR-08-2319. Epub 2009 Apr 21.

41.

Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR.

Cancer Res. 2009 Feb 15;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. Epub 2009 Feb 3.

42.

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC.

Cancer Chemother Pharmacol. 2009 Sep;64(4):741-51. doi: 10.1007/s00280-008-0923-3. Epub 2009 Jan 30.

43.

Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC, Baldwin MA.

Mol Cell Proteomics. 2009 Mar;8(3):467-80. doi: 10.1074/mcp.M800282-MCP200. Epub 2008 Nov 3.

44.

Unraveling the biologic and clinical complexities of HER2.

Park JW, Neve RM, Szollosi J, Benz CC.

Clin Breast Cancer. 2008 Oct;8(5):392-401. doi: 10.3816/CBC.2008.n.047. Review.

PMID:
18952552
45.

Ageing, oxidative stress and cancer: paradigms in parallax.

Benz CC, Yau C.

Nat Rev Cancer. 2008 Nov;8(11):875-9. doi: 10.1038/nrc2522. Review.

46.

Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.

Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC.

Mol Cancer Res. 2008 Jul;6(7):1250-8. doi: 10.1158/1541-7786.MCR-07-2110.

48.

Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.

Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC.

Oncogene. 2008 Sep 18;27(42):5643-7. doi: 10.1038/onc.2008.171. Epub 2008 May 26.

49.

Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.

Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33. doi: 10.1158/1055-9965.EPI-07-0726. Epub 2008 May 7.

50.

A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells.

Britton DJ, Scott GK, Schilling B, Atsriku C, Held JM, Gibson BW, Benz CC, Baldwin MA.

J Am Soc Mass Spectrom. 2008 May;19(5):729-40. doi: 10.1016/j.jasms.2008.02.008. Epub 2008 Mar 4.

Supplemental Content

Support Center